Dorsey & Whitney Trust CO LLC Acquires 278 Shares of GSK plc (NYSE:GSK)

Dorsey & Whitney Trust CO LLC raised its holdings in GSK plc (NYSE:GSK) by 2.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,506 shares of the pharmaceutical company’s stock after purchasing an additional 278 shares during the period. Dorsey & Whitney Trust CO LLC’s holdings in GSK were worth $389,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. FMR LLC boosted its holdings in GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares during the period. Fisher Asset Management LLC boosted its holdings in GSK by 1.4% in the 4th quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company’s stock valued at $637,061,000 after purchasing an additional 259,867 shares during the period. Primecap Management Co. CA boosted its holdings in GSK by 2.4% in the 3rd quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock valued at $607,222,000 after purchasing an additional 342,365 shares during the period. Equity Investment Corp boosted its holdings in GSK by 13.3% in the 4th quarter. Equity Investment Corp now owns 3,962,581 shares of the pharmaceutical company’s stock valued at $134,014,000 after purchasing an additional 466,327 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC boosted its holdings in GSK by 30.8% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after purchasing an additional 833,080 shares during the period. Institutional investors own 15.74% of the company’s stock.

GSK Price Performance

GSK stock opened at $40.41 on Tuesday. The company has a 50 day simple moving average of $35.61 and a 200 day simple moving average of $37.13. The stock has a market cap of $83.74 billion, a price-to-earnings ratio of 25.41, a P/E/G ratio of 1.12 and a beta of 0.58. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.93. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Research analysts anticipate that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a yield of 3.89%. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. GSK’s dividend payout ratio is currently 98.74%.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and dropped their target price for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Finally, Morgan Stanley assumed coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.